论文信息 - U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis - 字舞流文

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

C. Garnett | L. Burke | R. Pazdur | R. Sridhara | H. Lu | M. Rothmann | Atiqur Rahman | A. Farrell | H. Saber | J. Bullock | E. Kaminskas | J. Grillo | A. Deisseroth | Wei Chen | S. Brar | Jian Wang | Mark Rothmann